{"id":670157,"date":"2023-09-28T17:42:02","date_gmt":"2023-09-28T17:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=670157"},"modified":"2023-09-28T17:42:02","modified_gmt":"2023-09-28T17:42:02","slug":"familial-chylomicronemia-syndrome-market-anticipates-impressive-growth-trajectory-through-2032-asserts-delveinsight-akcea-arrowhead-pharma-ionis-lipigon-novartis-pfizer-uniqure-biopharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/familial-chylomicronemia-syndrome-market-anticipates-impressive-growth-trajectory-through-2032-asserts-delveinsight-akcea-arrowhead-pharma-ionis-lipigon-novartis-pfizer-uniqure-biopharma_670157.html","title":{"rendered":"Familial Chylomicronemia Syndrome Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Akcea, Arrowhead Pharma, Ionis, Lipigon, Novartis, Pfizer, UniQure Biopharma"},"content":{"rendered":"
\n
\"Familial<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Familial Chylomicronemia Syndrome market size in the 7MM was around USD 15 million in 2022, and it is estimated to increase by 2032 at a significant CAGR. As per DelveInsight, the Familial Chylomicronemia Syndrome Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Familial Chylomicronemia Syndrome and the launch of new therapies in the market.<\/div>\n

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Chylomicronemia Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Familial Chylomicronemia Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Familial Chylomicronemia Syndrome treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Familial Chylomicronemia Syndrome: An Overview<\/strong><\/p>\n

Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by an increase in the triglycerides (TGs) level due to a reduction in the LPL, which is an enzyme that helps to break down chylomicrons (CMs) in the body. The reduction in the LPL leads to the buildup of CMs which are rich in triglycerides.<\/p>\n

The diagnosis is mainly supported by the presence of markedly elevated TG concentrations and CM, the latter of which is normally rapidly cleared from the plasma following a meal. The current treatment involves the restriction of the dietary fat intake allied with traditional TG-lowering agents like fibrates, statins, and niacin’s. However, there is no US Food and Drug Administration (FDA) approved drug for the treatment of FCS, but in May 2019, Waylivra (volanesorsen) was conditionally approved by the European Commission (EC) for the treatment of FCS.<\/p>\n

Familial Chylomicronemia Syndrome Market Key Facts<\/strong><\/p>\n